Onkologie. 2019:13(4):157-160 | DOI: 10.36290/xon.2019.030

Enzalutamide in treatment of the metastatic castrate resistant prostate cancer

Igor Richter1,2, Josef Dvořák2
1 Onkologické oddělení, Krajská nemocnice Liberec, a. s.
2 Onkologická klinika 1. LF UK a Thomayerovy nemocnice, Praha

Metastatic castration-resistant prostate cancer is a severe disease. Recently, however, its therapy has been significantly enriched
adding novel treatment options extending patient overal survival. Enzalutamide targets multiple steps in the androgen-receptor
signaling pathway. In patients with metastatic castration-resistant prostate cancer, enzalutamid has become a cornerstone of
the treatment due to results of AFFIRM and PREVAIL studies. The overview article describes the current position of enzalutamid
in the treatment of this malignancy.

Keywords: prostate cancer, metastases, hormonal therapy, targeted therapy, toxicity

Published: September 15, 2019  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Richter I, Dvořák J. Enzalutamide in treatment of the metastatic castrate resistant prostate cancer. Onkologie. 2019;13(4):157-160. doi: 10.36290/xon.2019.030.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Ondrušová M, Mužík J, Kliment J, et al. Prostate cancer incidence and mortality in selected countries of central Europe. Klin Onkol 2011; 24: 126-132. Go to PubMed...
    2. Mottet N, Bellmunt J, van den Bergh RCN et al. EAU Guidelines on prostate cancer - update April 2014. Arnhem: european Association of Urology 2014: 172. Go to PubMed...
    3. Richter I, Dvořák J, Bartoš J. Možnosti chemoterapie v léčbě karcinomu prostaty. Klin Onkol. 2017; 30: 28-33. Go to original source... Go to PubMed...
    4. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantron plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-1512. Go to original source... Go to PubMed...
    5. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone plus prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-1520. Go to original source... Go to PubMed...
    6. Rušarová N, Študentová H. Současné možnosti léčby metastatického kastračně rezistentního karcinomu prostaty. Onkologie 2017; 11: 200-204. Go to original source...
    7. Sartor AO. Progression of metastatic castrate-resistant prostatae cancer: impact of therapeutic intervention in the post-docetaxel space. J Hematol Oncol 2011; 4: 18. Go to original source... Go to PubMed...
    8. Chen CD, Welsbie DS, Tran C et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2003; 10: 33-39. Go to original source... Go to PubMed...
    9. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer directed therapies targeting the androgen-receptor signaling axil. J Clin Oncol 2005; 23: 8253-8261. Go to original source... Go to PubMed...
    10. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790. Go to original source... Go to PubMed...
    11. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine 2012; 367: 1187-1197. Go to original source... Go to PubMed...
    12. Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine 2014; 371: 424-433. Go to original source... Go to PubMed...
    13. Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the Phase 3 PREVAIL Study. European Urology 2017; 71: 151-154. Go to original source... Go to PubMed...
    14. Fizazi K, Chi KN, de Bono JS, et al. Low incidence of corticosteroid-associated averse events on long-term exposure to low-dose prednison given with abiraterone acetate to patients with metastatic castration-resistant prostate cancer. Eur Urol 2016; 70: 438-444. Go to original source... Go to PubMed...
    15. Boyd LK, Mao X, Lu YJ. The complexity of prostate cancer: genomic alterations and heterogeneity. Nature Reviews. Urology 2012; 9: 652-664. Go to original source... Go to PubMed...
    16. Scher HI, Halabi S, Tannock IF, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. Journal of Clinical Oncology 2008; 26: 1148-1159. Go to original source... Go to PubMed...
    17. Brasso K, Thomsen FB, Schrader AJ, et al. Enzalutamide antitumour activity against metastatic castration-resistant prostate cancer previously treated with docetaxel and abiraterone: a multicentre analysis. European Urology 2015; 68: 317-324. Go to original source... Go to PubMed...
    18. Fuerea A, Baciarello G, Patrikidou A, et al. Early PSA response is an independent prognostic factor in patients with metastatic castration-resistant prostate cancer treated with next-generation androgen pathway inhibitors. European Journal of Cancer 2016; 61: 44-51. Go to original source... Go to PubMed...
    19. Scher HI, Heller G, Molina A, et al. Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. Journal of Clinical Oncology 2015; 33: 1348-1355. Go to original source... Go to PubMed...
    20. Lorente D, Olmos D, Mateo J, et al. Decline in circulating tumor cell count and treatment outcome in advanced prostate cancer. European Urology 2016; 70: 985-992. Go to original source... Go to PubMed...
    21. Heller G, Fizazi K, McCormack R, et al. The added value of circulating tumor cell enumeration to standard markers in assessing prognosis in a metastatic castration-resistant prostate cancer population. Clinical Cancer Research 2017; 23: 1967-1973. Go to original source... Go to PubMed...
    22. Taplin ME, Bubley GJ, Ko YJ, et al. Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. Cancer Research 1999; 59: 2511-2515. Go to PubMed...
    23. Coutinho I, Day TK, Tilley WD et al. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocrine-Related Cancer 2016; 23: T179-T197. Go to original source... Go to PubMed...
    24. Pal SK, Patel J, He M, et al. Identification of mechanisms of resistance to treatment with abiraterone acetate or enzalutamide in patients with castration-resistant prostate cancer (CRPC). Cancer 2018; 124: 1216-1224. Go to original source... Go to PubMed...
    25. Grossmann ME, Huang H, Tindall DJ. Androgen receptor signaling in androgen-refractory prostate cancer. Journal of the National Cancer Institute 2001; 93: 1687-1697. Go to original source... Go to PubMed...
    26. Buchler T, Bobek V, Kološtová K. Testování varianty androgenového receptoru AR-V7 pro výběr pacientů s kastračně refrakterním metastazujícím karcinomem prostaty k léčbě novými hormonálními léky. Klin Onkol 2018; 3: 9-14.
    27. Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamid and abirateron in prostate cancer. N Eng J Med 2014; 371: 1028-1038. Go to original source... Go to PubMed...
    28. Bernemann C, Schnoeller TJ, Luedeke M, et al. Expression of AR-V7 in Circulating Tumour Cells Does Not Preclude Response to Next Generation Androgen Deprivation Therapy in Patients with Castration Resistant Prostate Cancer. Eur Urol. 2017; 71(1): 1-3. Go to original source... Go to PubMed...
    29. Arora VK, Schenkein E, Murali R, et al. Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade. Cell 2013; 155: 1309-1322. Go to original source... Go to PubMed...
    30. Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Research 2008; 68: 6407-6415. Go to original source... Go to PubMed...
    31. Pfeiffer MJ, Smit FP, Sedelaar JP, et al. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Molekuliarna Meditsina 2011; 17: 657-664. Go to original source... Go to PubMed...
    32. Hamid AR, Pfeiffer MJ, Verhaegh GW, et al. Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Molekuliarna Meditsina 2013; 18: 1449-1455. Go to original source... Go to PubMed...
    33. Tan PS, Haaland B, Montero AJ, et al. Hormonal therapeutics enzalutamide and abirateron acetate in the treatment of metastatic castration-resistant prostate cancer (mCRPC) post-docetaxel - an indirection comparison. Clin Med Insights: Oncol 2014; 8: 29-36. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.